HIV cure: Controversy, consensus, and a consortium

AIDS Research and Human Retroviruses

Volumn 26, Issue 9, 2010, Pages 943-946

  Johnston, Rowena ^a  

^a Foundation for AIDS Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; MEDICAL RESEARCH; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV; HIV INFECTIONS; HUMANS;

EID: 77956390360     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0087     Document Type: Article

References (33)

1. Ho DD: Time to hit HIV, early and hard. N Engl J Med 1995;333(7):450-451.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, and Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295- 1300.
3. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, and Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278(5341):1291-1295.
4. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, and Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94(24): 13193-13197.
5. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, and Siliciano RF: Longterm follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4- T cells. Nat Med 2003;9(6):727-728.
6. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, and Siliciano RF: Latent infection of CD4- T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5(5):512-517.
7. Dahl V, Josefsson L, and Palmer S: HIV reservoirs, latency, and reactivation: Prospects for eradication. Antiviral Res 2010;85(1):286-294.
8. Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, and Lane HC: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96(26):15109-15114.
9. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, and Sékaly RP: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15(8):893-900.
10. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, and Siliciano RF: Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4- T cells. J Virol 2006;80(13):6441-6457.
11. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, and Siliciano RF: Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008;14(7):762-766.
12. Hatano H, Hayes T, Dahl V, Sinclair E, Lee T-H, Hunt P, Palmer S, Busch M, Shacklett B, and Deeks S: Raltegravir intensification in antiretroviral- treated patients exhibiting a suboptimal CD4- T cell response. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 101LB.
13. Wiegand A, Cossarini F, Poethke C, Kearney M, Spindler J, OShea A, Rehm C, Coffin J, Mellors J, and Maldarelli F: Raltegravir intensification does not reduce persistent HIV-1 Viremia in treatment-experienced patients. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 280.
14. de Laugerre C, Charreau I, Braun J, Néré M-L, de Castro1 N, Yeni P, Ghosn J, Simon F, Aboulker J-P, and Molina J-M: No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 weeks of raltegravir-containing therapy in patients with controlled viremia: A sub-study of the Randomized EASIER-ANRS 138 Trial. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 281
15. Evering T, Mehandru S, Poles M, Racz P, Tenner-Racz K, Mohri H, Prada N, Garmon D, Parker T, and Markowitz M: The antiviral and immunological effects of intensification of suppressive ART with maraviroc, a CCR5 antagonist. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 283.
16. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, and Martinez-Picado J: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; published online 14 March 2010; doi:10.1038/nm.2111.
17. Yukl S, Shergill A, Gianella S, Choi A, Girling V, Downing M, Lampiris H, Guenthard H, Wong J, Havlir D, and the PLUS Study Group: Effect of raltegravir-containing intensification on HIV burden and T cell activation in the gut of HIV- adults on suppressive ART. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 279.
18. Wilkin T, Lalama C, Tenorio A, Landay A, Ribaudo H, McKinnon J, Gandhi R, Mellors J, Currier J, and Gulick R: Maraviroc intensification for suboptimal CD4- cell response despite sustained virologic suppression: ACTG 5256. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 285.
19. Gutiérrez C, Diaz L, Hernández-Novoa1 B, Vallejo A, Page C, Lorente R, Madrid N, Palmer S, Muñoz-Fernández M Á , and Moreno S: Effect of the intensification with a CCR5 antagonist on the decay of the HIV-1 latent reservoir and residual viremia. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 284
20. Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, and Lane HC: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96(26):15109-15114.
21. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, and Nunnari G: IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115(1):128-137.
22. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, and Margolis DM: Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005;366(9485):549555.
23. Kauder SE, Bosque A, Lindqvist A, Planelles V, and Verdin E: Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009;5(6):e1000495.
24. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, and Van Lint C: Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection. PLoS One 2009;4(6):e6093.
25. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, and Arkin AP: Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010;84(12):5958-5974.
26. Choudhary SK, Archin NM, and Margolis DM: Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(-) T cells. J Infect Dis 2008;197(8):1162-1170.
27. Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, and Clements JE: Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4- T cells. J Infect Dis 2010;201(8):1132-1140.
28. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, and Hofmann WK, Thiel E: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360(7):692-698.
29. Hütter G, Allers K, and Schneider T: The additional use of viral entry inhibitors during autologous hematopoietic stem cell transplantation in patients with non-Hodgkins lymphoma and HIV-1 infection. Biol Blood Marrow Transplant 2009 Nov 2. (http//dx.doi.org/10.1016/j.bbmt.2009.10.030).
30. Deeks SG and Walker BD: Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27(3):406-416.
31. Choudhary SK, Vrisekoop N, Jansen CA, Otto SA, Schuitemaker H, Miedema F, and Camerini D: Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007;81(16):8838-8842.
32. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, and Pomerantz RJ: The challenge of finding a cure for HIV infection. Science 2009;323(5919):1304-1307.
33. http://www.amfar.org/lab/grants/default.aspx?id8358